Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Three Fool.com contributors have identified what they view as magnificent stocks trading at under $100 to buy in November.

Lacy listed Keytruda, a cancer treatment, costs about R100 000 per cycle. “By costs, we mean not just treatment and care but the emotional and physical toll that a cancer diagnosis has on a person.

Exelixis boasts a star drug that won't face generic competition ... That beat Merck's cancer immunotherapy Keytruda. To put this into context, Keytruda generated sales of $25 billion last year ...

In the meantime, Cabometyx should continue being a star performer for Exelixis ... That beat Merck's cancer immunotherapy Keytruda. To put this into context, Keytruda generated sales of $25 ...

Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock ...

TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line ...

A phase 1 trial is being conducted to evaluate the combination of PT886 and Keytruda in patients with claudin 18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. A new phase 1 ...

Werewolf’s lead drug candidate, WTX-124, is being developed to treat solid tumors and is under investigation as both a monotherapy and in combination with Keytruda ... s 5-star analyst, Jason ...

The stock gained momentum in early October, and Clover subsequently announced the Centers for Medicare and Medicaid Services has increased the star rating of Clover's PPO Medicare Advantage plans ...

Keytruda is also approved for first-line use alongside chemo and trastuzumab in HER2-positive gastric and GEJ cancers. Gilead and Arcus are already running the phase 3 STAR-221 trial of their ...